INHIBITION OF [3H]LEVETIRACETAM BINDING TO BRAIN MEMBRANES BY ZINC AND COPPER
Abstract number :
1.219
Submission category :
7. Antiepileptic Drugs
Year :
2008
Submission ID :
8441
Source :
www.aesnet.org
Presentation date :
12/5/2008 12:00:00 AM
Published date :
Dec 4, 2008, 06:00 AM
Authors :
Jean Bidlack, B. Knapp and H. Morris, III
Rationale: Levetiracetam (LEV) has been reported to bind to the SV2A vesicular protein (Gillard et al., Eur. J. Pharmacol. 478:1-9, 2003), and to inhibit calcium-induced calcium release in hippocampal neuronal cultures (Nagarkatti et al., Neurosci. Lett. 436:289-293, 2008). Previously, we reported that the divalent cations, Mg2+, Ca2+, Sr2+, and Ba,2+, stimulated [3H]LEV binding to guinea pig brain membranes (Bidlack et al., Epilepsia 48(supple. 6): 316-317, 2007). Zinc and copper are endogenous transition metals that can be synaptically released during neuronal activity. Zn2+ interacts with many ion channels and functions as an endogenous modulator of neuronal excitability by modulating ligand-gated ion channels such as the NMDA glutamate and the GABAA receptors. Zn2+ and Cu2+ concentrations at the synaptic cleft have been estimated to peak at 100 - 300 μM (Horning et al., Brain Res. 852:56-61, 2000). The purpose of this study was to determine if Zn2+ and Cu2+ altered [3H]LEV binding to neuronal membranes. Methods: [3H]LEV (18 Ci/mmol) was custom labeled by GE Healthcare. Guinea pig brain membranes were incubated at 4oC with varying concentrations of ZnCl2 or CuCl2 and 10 nM [3H]LEV for 4 hrs. Nonspecific binding was measured by the inclusion of 100 μM unlabeled LEV. To terminate binding, membranes were filtered through glass fiber filters, soaked in 0.25% polyethyleneimine. The filters were washed with cold 50 mM Tris-HCl, pH 7.5, and were counted in a scintillation counter. Results: [3H]LEV binding to brain membranes was inhibited by Zn2+ and Cu2+ in a concentration-dependent manner. Zn2+ had an IC50 value of 62 ± 4.2 μM for the inhibition of the binding of 10 nM [3H]LEV to neuronal membranes. An Imax value of 74 ± 4.5% was obtained, meaning that approximately 25% of the [3H]LEV binding was not inhibited by Zn2+ at concentrations up to 3 mM. CuCl2 inhibited [3H]LEV binding with an IC50 value of 250 ± 72 μM and an Imax value of 95 ± 5.2%, meaning that Cu2+ at physiological concentrations inhibited virtually all of the [3H]LEV binding. Conclusions: [3H]LEV binding is tightly regulated by cations, particularly Zn2+ and Cu2+. Zn2+ and Cu2+ are highly concentrated in several brain regions, including the hippocampus. A role for Zn2+ in epilepsy was suggested by its modulatory actions on neuronal activity, the prominence of Zn2+-containing pathways in seizure-prone brain regions, abnormalities of cerebral Zn2+ in epileptic animals, and the effects of Zn2+ manipulations on seizures susceptibility (Erickson et al., J. Neurosci. 17:1271-1281, 1997). Collectively, the results from this study suggest that [3H]LEV binds to a protein that is directly modulated by cations, particularly Zn2+ and Cu2+. By examining [3H]LEV binding to proteins known to bind Zn2+ and Cu2+, the identification of the LEV binding site involved in its anti-epileptic effects may be determined.
Antiepileptic Drugs